The link between malignancy and hemostasis is not new. The first alarming signal that antiplatelet therapy may cause excess of solid cancers was observed in the prasugrel arm of TRITON-TIMI 38 trial and confirmed by the Food and Drug Administration (FDA). Later, until TRACER FDA review, the data remain inconclusive, probably because of the awareness of drug manufacturers of such catastrophic association resulted in missing delayed outcomes, discontinuations, or/and incomplete follow-up, suggesting bias. Recently, however, 4 important pieces of the puzzle emerge, namely vorapaxar, apixaban FDA reviews, DAPT for clopidogrel and prasugrel, and PEGASUS for ticagrelor confirming that cancer signal after antithrombotics is not an artifact, or play of chance, but rather a scaring reality. Independently, a Danish registry for almost 126,000 myocardial infarction (MI) survivors without a history of cancer were matched with more than 3 million subjects with no history of either MI or cancer. Results suggested that cancer rate was more than doubled (173.5 per 10,000 person-years) in the MI survivors versus 85.2 per 10,000 person-years for their peers without MI over 17-year follow-up. Despite the existing cancer signal, survival of such patients may be worsened because chronic antithrombotic regimens may cause not only more cancer dissemination but promotion of more aggressive unclassified malignancies associated with potentially shorter survival. We, therefore, matched the survival after solid cancers in TRITON prasugrel arm with the publically available evidence from 2 reputable independent international census datasets.